SANA BIOTECHNOLOGY INC (SANA) — insider trading
Health Care · NASDAQ
SANA BIOTECHNOLOGY INC (SANA) has 20 reported SEC Form 4 insider transactions in our data (latest 2026-10-05).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-10-05 | Bishop Hans Edgar | Director | Grant / award / vesting | 8,680 | — | $0 | Form 4 |
| 2026-08-27 | PATEL DHAVALKUMAR DHIRAJLAL | Officer (EVP, Chief Scientific Officer) | Shares withheld for taxes / exercise cost | 41,158 | $4.11 | $169.2K | Form 4 |
| 2026-08-26 | PATEL DHAVALKUMAR DHIRAJLAL | Officer (EVP, Chief Scientific Officer) | Option exercise / conversion (derivative) | 125,000 | — | $0 | Form 4 |
| 2026-08-26 | PATEL DHAVALKUMAR DHIRAJLAL | Officer (EVP, Chief Scientific Officer) | Option exercise / conversion | 125,000 | — | $0 | Form 4 |
| 2026-07-06 | Bishop Hans Edgar | Director | Grant / award / vesting | 6,297 | — | $0 | Form 4 |
| 2026-06-04 | NELSEN ROBERT | Director, 10% owner | Grant / award / vesting (derivative) | 90,000 | — | $0 | Form 4 |
| 2026-06-04 | Bilenker Joshua H. | Director | Grant / award / vesting (derivative) | 90,000 | — | $0 | Form 4 |
| 2026-06-04 | Bishop Hans Edgar | Director | Grant / award / vesting (derivative) | 90,000 | — | $0 | Form 4 |
| 2026-06-04 | Mulligan Richard | Director | Grant / award / vesting (derivative) | 90,000 | — | $0 | Form 4 |
| 2026-06-04 | REICIN ALISE | Director | Grant / award / vesting (derivative) | 90,000 | — | $0 | Form 4 |
| 2026-06-04 | Seitz Michelle | Director | Grant / award / vesting (derivative) | 90,000 | — | $0 | Form 4 |
| 2026-06-04 | Rosiello Robert L. | Director | Grant / award / vesting (derivative) | 90,000 | — | $0 | Form 4 |
| 2026-06-04 | Yang Patrick Y | Director | Grant / award / vesting (derivative) | 90,000 | — | $0 | Form 4 |
| 2026-04-06 | Bishop Hans Edgar | Director | Grant / award / vesting | 7,763 | — | $0 | Form 4 |
| 2026-03-09 | Harr Steve | Director, Officer (President & CEO) | Shares withheld for taxes / exercise cost | 12,819 | $3.10 | $39.7K | Form 4 |
| 2026-03-09 | Harr Steve | Director, Officer (President & CEO) | Shares withheld for taxes / exercise cost | 11,526 | $3.13 | $36.1K | Form 4 |
| 2026-03-07 | Harr Steve | Director, Officer (President & CEO) | Option exercise / conversion (derivative) | 50,000 | — | $0 | Form 4 |
| 2026-03-07 | Harr Steve | Director, Officer (President & CEO) | Option exercise / conversion | 50,000 | — | $0 | Form 4 |
| 2026-03-06 | Harr Steve | Director, Officer (President & CEO) | Option exercise / conversion (derivative) | 41,666 | — | $0 | Form 4 |
| 2026-03-06 | Harr Steve | Director, Officer (President & CEO) | Option exercise / conversion | 41,666 | — | $0 | Form 4 |
Ask the chat about SANA's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: SANA BIOTECHNOLOGY INC (SANA).
Last updated 2026-10-05 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.